Early findings from Phase I and Phase II clinical trials using a new
class of drug to treat patients with triple-negative breast cancer are
showing promising results. Known as poly (ADP-ribose) polymerase, or
PARP inhibitors, these new agents received considerable attention at
the American Society of Clinical Oncology meeting in June.
Cheryl Jolly, in the related story, is now enrolled in a Phase III trial, and her tumor is shrinking...
People often do not make a distinction between the terms integrative medicine and alternative medicine. Below is the mission statement of...